Jefferies analyst Maury Raycroft lowered the price target on Precision BioSciences Inc. (NASDAQ: DTIL) to $19.00 (from $21.00) while maintaining a Buy rating.

The analyst commented, "Near-term setup is attractive w/ 2 very differentiated programs: 1) HBV ph.I progressing well through dose escalation and data this yr @ med conferences focused on safety, stopping NUCs, testing for functional cure, and moving into Part 2 expansion cohorts; 2) DMD IND cleared in early '26 w/ initial data from multiple pts by YE26; KOL event 3/17 @ 9AM ET. Cash through 2028 beyond multiple clin inflection points."